Merck & Co has made another move towards diversifying its pipeline and reducing its reliance on blockbuster cancer drug Keytruda, pledging $525 million to an alliance with Synthekine initially ...
Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback